An observational study in Chronic Lymphocytic Leukemia, sponsored by AstraZeneca. Active, not recruiting at 41 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by AstraZeneca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca — 6 open to participants now, 21 under way, 5 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · AstraZeneca.
Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one is the 6th largest by enrollment of the 12 observational ones that give a count, is one of 4 that started in 2023, is one of 12 observational ones, reaches primary completion later than 12 of the 20 other live ones, and was the 35th registered.
2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →6 of the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
AstraZeneca · Sites in Belarus
Ages 18+
AstraZeneca · Sites in France
AstraZeneca · Sites in United States, Australia, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Canada and 7 more countries
Ages 18+
By country, each count listing its studies:
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 15 · Phase 3 7 · Phase 4 1
First in 2005; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is close to the median of 148 across 216 observational studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 103 across the 29 interventional studies, 136 across the 12 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
5 of the studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT06548152AstraZenecaAQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database | 2026-12-31 |
| NCT05140369AstraZenecaCLL Therapy Approaches in Russia | 2027-03-31 |
| NCT06205498AstraZenecaAcalabrutinib Real World Italian obSErvational Study -ARISE | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the adults in the Western world, with an annual incidence of approximately 5 cases per 100,000 inhabitants in Italy.
Acalabrutinib (CalquenceTM), a selective second-generation Bruton Tyrosine Kinase (BTK) inhibitor developed by AstraZeneca, has been assessed for the treatment of CLL in three phase III clinical trials, ELEVATE-TN (treatment-naïve CLL), ASCEND and ELEVATE R/R (relapsed and refractory CLL). These pivotal randomized clinical trials established the efficacy and safety of acalabrutinib in patients with CLL and based on these data CalquenceTM received EMA approval in November 2020 for the treatment of CLL in adult patients and received AIFA (Agenzia Italiana del Farmaco) reimbursement as monotherapy in December 2021. However, further data are still required to evaluate the use of acalabrutinib in the real-life conditions of post-marketing authorization.
The primary aim of ARISE study is to evaluate the time to treatment discontinuation and reasons for discontinuation for acalabrutinib in a real world setting of patients with CLL. This study will provide the first real-world data on the use of acalabrutinib in the treatment of CLL in Italy.
Study design:
This is an Italian non-interventional / observational, multicenter, longitudinal secondary data usage study based on a retrospective cohort of patients with CLL, who initiated treatment with acalabrutinib between 1st May 2021 and 30th April 2022 (index date), regardless of the treatment status at the time of inclusion. Each patient will be followed-up up to 5 years since the last enrolled patient index date (therefore for a maximum of 72 months). Five data extraction timepoints are planned for the investigators to proceed with secondary data extraction from patients' medical records and data entry into the electronic case report form (eCRFs).
Data Source(s):
Source documents (paper or electronic) are those in which patient data are recorded and documented for the first time as part of patients' path of care (e.g., patient's hospital records, pharmacy dispensing records).
A standardized, validated eCRF will be developed to capture data extracted from source documents at each participating site.
Study Population:
All consecutive adult patients with CLL who initiated treatment with acalabrutinib over the period between 1st May 2021 and 30th April 2022, according to Italian legislation dlg 219/2006 art.125.
Outcome(s):
The primary outcome is the time to acalabrutinib discontinuation (defined as time in days from start date of acalabrutinib treatment to end date of acalabrutinib treatment).
Secondary outcomes include: Time from diagnosis to start of acalabrutinib, immunophenotype, CLL clinical stage (Binet), FISH profile, mutations, karyotype, CLL treatments before acalabrutinib, socio-demographic characteristics at baseline, medical history, concomitant treatments, COVID-19 prophylaxis and treatments, constitutional symptoms, patient clinical status, ECG/TTE, complete blood count with differential, serum chemistry, HIV and Hepatitis serology, active haemolysis, time to acalabrutinib discontinuation, acalabrutinib treatment (dosage, relative changes, temporary interruption/permanent discontinuation).
Exploratory outcomes include: Time to progression, Time to death, CLL status (according to iwCLL), Time to Next Treatment, Time to progression on next line treatment, reasons for ending of CLL treatments following acalabrutinib discontinuation, visits and hospitalizations due to CLL or suspected ADR during acalabrutinib treatment.
Investigators participating in this observational study should include all patients with CLL who initiated treatment with acalabrutinib over the period between May 1st, 2021 and April 30th, 2022, regardless of the treatment status at the time of inclusion. Thus, at the time of enrolment and retrospective data collection, patients may still be on treatment or have stopped treatment for any reason.
Inclusion Criteria All consecutive patients with CLL who received acalabrutinib according to Italian legislation dlg 219/2006 art.125 will be eligible for inclusion in the study, subject to site agreement and patient consent to participate.
Patients must meet the following criteria for study entry:
Exclusion Criteria
Patients who meet any of the following criteria will be excluded:
1. Acalabrutinib treatment initiation before 1st May 2021 or after 30th April 2022.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients with CLL who initiated treatment with acalabrutinib over the period between 1st May 2021 and 30th April 2022, according to Italian legislation dlg 219/2006 art.125
Also known as: Calquence
time to acalabrutinib discontinuation
The primary outcome is the time to acalabrutinib discontinuation (defined as time in days from start date of acalabrutinib treatment to end date of acalabrutinib treatment) Kaplan-Meier median time to acalabrutinib discontinuation (defined as time in days from start date of acalabrutinib treatment to end date of acalabrutinib treatment). (Note: Any acalabrutinib treatment suspension \>28 days is defined as discontinuation. Any acalabrutinib treatment suspension ≤ 28 days is defined as interruption and should not be considered for the analysis of the primary objective.
Time frame: through study completion, an average of 5 years
demographic and clinical characteristics of CLL patients treated with acalabrutinib
To describe demographic and clinical characteristics of CLL patients treated with acalabrutinib, by treatment line and potential associations with acalabrutinib permanent discontinuation.
Time frame: baseline
describe acalabrutinib treatment patterns
Duration of acalabrutinib suspension= time from the date of last dose before suspension to the date of acalabrutinib restart. Frequency of acalabrutinib interruptions Time to interruption= time from the first dose of acalabrutinib to the date of last dose before interruption Proportion of each reason for treatment ending (adverse events, disease progression, compliance issues, patient's decision, physician's choice, death, other) In case of discontinuation for adverse event: proportion of each type of adverse event. Frequency of acalabrutinib dose changes Proportion of each reason for dose change Time to dose change= time from the first dose of acalabrutinib to the first dose administered at the new dosage Mean dose at last acalabrutinib use Relative dose intensity= received dose/prescribed dose (where received dose is the total dose actually received by patient during the whole observation period; prescribed dose is the dose at the acalabrutinib )initiation
Time frame: through study completion, an average of 5 years
CLL clinical stage
according to Binet staging system (stage A, B, C) according to Eichhorst et al., 2020.
Time frame: baseline
FISH profile
del(11q) del(17p); trisomy 12; del(13q); normal
Time frame: baseline
Date of birth
month/year
Time frame: baseline
gender
male or famale
Time frame: baseline
Height
cm
Time frame: baseline
Weight
Kg
Time frame: throught study completion, an average of 5 years
Body Mass Index
kg/m2
Time frame: Through study completion, an average of 5 years
Medical illness burden
CIRS-G scale
Time frame: Through study completion, an average of 5 years
Red blood cell count
x10\^12/L
Time frame: Through study completion, an average of 5 years
White blood cell count
x10\^9/L
Time frame: Through study completion, an average of 5 years
platelets count
x10\^9/L
Time frame: Through study completion, an average of 5 years
hemoglobin
gr/dL
Time frame: Through study completion, an average of 5 years
differential count of lymphocytes and neutrophils
Time frame: Through study completion, an average of 5 years
creatinine clearance (mL/min), aspartate transaminase (AST; U/L), alanine transaminase (ALT; U/L), gamma-glutamyl transferase (GGT; U/L), bilirubin (mg/dL), LDH (U/L), β2-microglobulin (mg/dL), IgG, IgA, IgM levels (mg/dL)
Time frame: baseline
Anti-HIV antibodies test and Hepatitis serology tests including hepatitis B surface antigen (HbsAg), hepatitis B surface antibody (HbsAb), hepatitis B core antibody (anti-HBc), and hepatitis C (HCV) antibody
Time frame: baseline
measure effectiveness of acalabrutinib
To measure effectiveness of acalabrutinib treatment in patients with CLL in terms of: Progression Free Survival (PFS), Overall Survival (OS), Overall Response Rate (ORR - categorization according to iwCLL), Time To Next Treatment (TTNT) Kaplan-Meier median time to progression (defined as time from start date of acalabrutinib treatment to the first assessment of disease progression) Kaplan-Meier median time to Death (defined as time from start date of acalabrutinib treatment to death) Proportion of patients with Complete Response, Partial response, Partial Response with lymphocytosis or Stable Disease Kaplan-Meier median time to next treatment (defined as time from start date of acalabrutinib treatment to the first consecutive treatment)
Time frame: through study completion, an average of 5 years
evaluate effectiveness of CLL treatments following acalabrutinib discontinuation
To evaluate effectiveness of CLL treatments following acalabrutinib discontinuation in terms of PFS2, OS and ORR by treatment and relative causes of discontinuation. Kaplan-Meier median time to progression (defined as time from start date of acalabrutinib treatment to progression) on next-line treatment The time to death and the overall response are computed as described for the exploratory objective n.1 Proportion of each reason for discontinuation of CLL treatments following acalabrutinib (patient's decision, physician's choice, adverse events, death, other, unknown)
Time frame: through study completion, an average of 5 years
estimate Healthcare Resources Utilization
To estimate Healthcare Resources Utilization by patients with CLL, in terms of hospitalizations and visits (routine follow-up, outpatient visits and emergency visits) Total visits= number of all visits performed during the observation period Total hospitalizations= number of all hospitalizations performed during the observation period Mean, minimum and maximum total visits Mean, minimum and maximum total hospitalizations Mean, minimum and maximum hospitalizations duration In case of visits and hospitalization due to AE suspected of relationship with acalabrutinib (ADR): proportion of each type of adverse event.
Time frame: through study completion, an average of 5 years
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Apr 2027, 44 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Lymphocytic, Chronic, B-Cell →